Clinical Trial

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 21, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-22; most recent amendment 2025-05-20.
Status change: Recruiting → Active, Not Recruiting 2025-05-20
Trial Details
NCT Number NCT06383052
Lead Sponsor Norroy Bioscience Co., LTD
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 30 participants
Start Date 2024-04-26
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-21